DNA Sequencing of Bone Marrow Is Predictive of ALL Relapse Following Treatment With Tisagenlecleucel
December 02, 2021

DNA sequencing to detect minimal residual disease and eventual relapse was more accurate than flow cytometry for adult and pediatric patients with acute lymphoblastic leukemia who have been treated with tisagenlecleucel.

Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
December 02, 2021

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
December 02, 2021

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Updated Safety Data and Treatment Selection in nmCRPC
December 02, 2021

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

Adverse Events with Next-Generation Androgen Receptor Inhibitors in nmCRPC
December 02, 2021

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.

Oncology Peer Review On-The-Go: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
December 02, 2021

Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.

Unmet Needs and Future Directions
December 02, 2021

Zofia Piotrowska, MD, discusses unmet needs, novel treatment strategies and future perspectives for patients with EGFR exon 20-positive NSCLC.

Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC
December 02, 2021

Zofia Piotrowska, MD, shares insights on factors to consider when selecting the appropriate therapy for patients with EGFR exon 20-positive NSCLC.

Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC
December 02, 2021

Zofia Piotrowska, MD, evaluates the use of mobocertinib in patients with NSCLC and EGFR exon 20 insertions and provides updated results from key trials of mobocertinib in EGFR exon 20-positive NSCLC.

Assessing Treatment Response in Myelofibrosis
December 02, 2021

Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.